Lab study explores iron chelation in Parkinson's and ALS cells
NCT ID NCT02880033
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study used blood cells from 90 people with Parkinson's disease, ALS, or healthy volunteers to see how the drug deferiprone affects cell stress and energy. The goal was to learn more about the disease process, not to treat patients. Results may guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Roger Salengro, CHRU de Lille
Lille, France
Conditions
Explore the condition pages connected to this study.